Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EXG-5003
- Development stage
- Phase 2
- Lead developer
- Elixirgen Therapeutics
- Modality
- mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
EXG-5003 is a temperature-sensitive, intradermally administered, controllable self-replicating RNA (c-srRNA) vaccine that encodes the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. Developed by Elixirgen Therapeutics, it is designed to induce strong T cell-mediated immunity against COVID-19. Unlike conventional mRNA vaccines, EXG-5003 does not use lipid nanoparticles for delivery and is active at skin temperature (~33°C), but inactive at core body temperature (~37°C), potentially improving safety and reducing off-target effects. Clinical trials have shown that EXG-5003 elicits antigen-specific cellular immunity with a favorable safety profile and may prime long-term cellular responses to subsequent approved mRNA vaccines[1][4][5].
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on EXG-5003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EXG-5003.